SRZNW
Surrozen, Inc.
A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.
WARRANTUnderlying: SRZNCUSIP: 86889P117HealthcareUS1 holder
Warrant expiring August 1, 2031
Total Value
$1.8K
Total Shares
108.3K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
